Accordingly, trans‐well assays demonstrated that savolitinib successfully reversed the promotive effect of RNASET2 deficiency on the migration and invasion of HCC cells by inactivating MET (Figure S8D,E, Supporting Information). Here, RNASET2 is linked to hepatocellular carcinoma.